Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
6D tau
Namespace
HBP
Namespace Version
None
Pattern
.*

Appears in Networks 1

In-Edges 10

a(HBP:"I-2") increases act(p(HBP:"6D tau", frag("2_18"))) View Subject | View Object

Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) anterograde FAT inhibition. PubMed:21734277

a(HBP:"ING-135") increases act(p(HBP:"6D tau", frag("2_18"))) View Subject | View Object

Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) anterograde FAT inhibition. PubMed:21734277

bp(GO:"anterograde axonal protein transport") association p(HBP:"6D tau", frag("2_18")) View Subject | View Object

As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT. PubMed:21734277

act(p(HBP:"6D tau")) association p(HBP:"6D tau", frag("2_18")) View Subject | View Object

As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT. PubMed:21734277

p(HBP:"AT8 tau") causesNoChange act(p(HBP:"6D tau", frag("2_18"))) View Subject | View Object

Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ. PubMed:21734277

p(HBP:TNT1) association p(HBP:"6D tau", frag("2_18")) View Subject | View Object

To evaluate the relevance of these find- ings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD. PubMed:21734277

path(MESH:"Alzheimer Disease") association act(p(HBP:"6D tau", frag("2_18"))) View Subject | View Object

These data indicated that increased PAD exposure, as revealed by TNT1 immunoreac- tivity, occurs early in AD and remains present throughout the disease process. PubMed:21734277

path(MESH:"Alzheimer Disease") association act(p(HBP:"6D tau", frag("2_18"))) View Subject | View Object

Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ. PubMed:21734277

Out-Edges 11

p(HBP:"6D tau", frag("2_18")) association act(p(HBP:"6D tau")) View Subject | View Object

As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) association bp(GO:"anterograde axonal protein transport") View Subject | View Object

As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) increases bp(GO:"anterograde axonal protein transport") View Subject | View Object

Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an- terograde FAT by activating the PP1–GSK3 cascade. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) decreases p(HBP:"endogenous axoplasmic phosphatases") View Subject | View Object

P-c-Jun was dephosphorylated to a greater extent in PAD peptide-perfused axoplasms than their scrambled peptide- perfused counterpart (Fig. 5F ), suggesting that the PAD peptide induced activation of endogenous axoplasmic phosphatases. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) decreases act(p(MESH:"Glycogen Synthase Kinase 3")) View Subject | View Object

A trend of elevated GSK3 activity (􏰈32%) relative to PKC activity ( p 􏰄 0.28, paired t test; n 􏰄 3) was observed for axoplasms incubated with the PAD peptide (mean 􏰄 4.9 􏰉 2.5), compared with those incubated with scram- bled peptide (mean 􏰄 3.7 􏰉 1.7), which supports the results from vesicle motility assays. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) decreases act(p(MESH:"Glycogen Synthase Kinase 3")) View Subject | View Object

Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an- terograde FAT by activating the PP1–GSK3 cascade. PubMed:21734277

p(HBP:"6D tau", frag("2_18")) association p(HBP:TNT1) View Subject | View Object

To evaluate the relevance of these find- ings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD. PubMed:21734277

act(p(HBP:"6D tau", frag("2_18"))) association path(MESH:"Alzheimer Disease") View Subject | View Object

These data indicated that increased PAD exposure, as revealed by TNT1 immunoreac- tivity, occurs early in AD and remains present throughout the disease process. PubMed:21734277

act(p(HBP:"6D tau", frag("2_18"))) association path(MESH:"Alzheimer Disease") View Subject | View Object

Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ. PubMed:21734277

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.